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1. Introduction
Hepatitis C is one of the commonest chronic viral infections world-wide and has major health‐
care implications. According to World Health Organization (WHO), the estimated prevalence
of chronic HCV infection world-wide ranges from 0.1% to more than 12%, equating to approxi‐
mately 170 million chronic carriers and incidence of 3-4 million new cases per year (Carbone et
al., 2011). Chronic kidney disease (CKD) in general is present in approximately 10% of the
population with many of these patients requiring renal replacement therapy in the form of dialysis
and or kidney transplant. A major cause of morbidity and mortality in dialysis patients and kidney
transplant recipients is liver disease secondary to hepatitis C virus (HCV) infection. The
prevalence of HCV infection is high among renal transplant donors, recipients, and in end stage
renal disease (ESRD) patients on dialysis. When HCV infection is present in this group of patients,
it has major implications (Scott et al., 2010; Goodkin et al., 2003; Carbone et al., 2011). The major
factors associated with this increased relative risk of HCV infection in dialysis patients as opposed
to general population are overall exposure of blood products, age, and duration of dialysis (Periera
& Levey, 1997; Finelli et al., 2005; Fissell et al., 2004). On the other hand, some recent reports
indicate possible decline in prevalence of HCV infection in dialysis patients (Carbone et al., 2011;
Scott et al., 2010; Finelli et al., 2005; Fissell et al., 2004; Jadoul et al., 2004; Fribrizi et al., 2002). This
decline could be related to the use of erythropoiesis-stimulating agents that consequently lead
to decrease in blood transfusions, and progressive enhancement of dialysis conditions to control
infections. In developed countries, the prevalence of HCV infection is higher in renal trans‐
plant recipients than in dialysis patients, major contributing factors being longer survival of the
former with more exposure to blood products, and most probably dialysis.
2. Natural history of HCV infection, morbidity and mortality in transplant
HCV RNA can be detected in the blood after 1-3 weeks of first exposure. In majority of the HCV
acute infection cases the patients are asymptomatic, however the disease can have a fulminant
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course. The natural history of Hepatitis C infection is quite variable with disease spectrum
varying from mild to severe hepatitis, hepatic cirrhosis, and hepatocellular carcinoma. In 60-85%
of these cases, HCV RNA can be detected for 6 months or longer. 10-15% of these chronic patients
progress to develop liver cirrhosis (National Institute of Health [NIH], 2002). The virus is very
slow to progress with almost no signs or symptoms in the first few years or decade. The most
reliable tool to examine the progression of HCV liver damage is histologic evaluation of liver
biopsy. The activity of liver disease can fluctuate, however, once there is fibrosis the damage is
considered to be irreversible and progressive. Poynard, in 2001, reported that the average time
of HCV infection to progress to liver cirrhosis is about 30 years, ranging from 13 years (for men
who drank and were infected after the age of 40 years) to 42 years (for women who did not drink
and were infected before the age of 40) (Poynard et al., 2001).
HCV infection has been associated independently with increased mortality in Hemodialysis
patients as shown by several studies including Dialysis Outcomes and Practice Patterns
(DOPPS) conducted over three continents (Goodkin et al., 2003; Fibrizi, 2004, 2007).
Transplant recipients from HCV positive donors have a higher rate of fulminant or severe
hepatitis and liver disease in general. The literature shows some controversy in results
presented by various studies regarding survival. The overall survival and specifically of the
allograft survival for HCV infected kidney transplant recipients are much worse than non-
infected renal transplant recipients (Figures 1 & 2) (Pedroso et al., 2006). Several studies have
shown that although recipients of organs from HCV infected donors have higher rates of liver
disease, there is no solid evidence of decreased overall survival rate (Periera, 1991, 1995;
Mendez et al., 1995). On the other hand, there are some other studies that show contrary results
with recipients of organs from HCV infected donors to have significantly higher morbidity
mainly due to liver disease and reduced overall survival with limited life expectancy (Pirsch
et al., 1995). The presence of liver damage depending on the severity as determined by biopsy
is a strong predictor of liver failure and death post-transplantation. Despite the ongoing
controversy, majority of the data shows increased morbidity due to higher rate of liver disease.
However, there is no consensus on lack of adverse effect on survival by initial studies that
mostly represented comparatively small number of cases and short period of followup. Fabrizi
and colleagues pooled these single studies in a meta-analysis and showed that anti HCV
positive status is an independent and significant risk factor for death and graft failure after
kidney transplantation with estimated relative risk of 1.79 and 1.56 respectively. In a recent
study, Scott and colleagues also showed prevalence of HCV infection in renal transplant
recipients to be 1.8% and reported the patient survival to be 77% and 90% at 5 years and 50%
and 79% at 10 years for HCV antibody positive and HCV antibody negative groups. The most
common causes of death in HCV positive kidney transplant recipients were cardiovascular
disease, malignancy, and liver failure (Scott et al., 2010). In addition to increased mortality,
Zylberberg et al found a significantly increased yearly progression rate of liver inflammation
and fibrosis in HCV infected renal transplant recipients than immunocompetent group
(Zylberberg et al., 2002). Alric and colleagues, on the contrary, showed the annual progression
of liver fibrosis to be significantly lower in renal transplant recipients than patients with HCV
and normal renal function (Alric et al., 2002). Reasons for the above mentioned difference is
not clear. There is strong evidence that transplantation with kidney from HCV infected donor
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is significantly associated with improved survival as opposed to remaining on dialysis on
transplant wait list (Abbott et al., 2004; Periera et al., 1998; Knoll et al., 1997; Maluf et al.,
2007). Findings suggest that detrimental effect of transplantation in association with HCV
infection does not outweigh its long term benefits on survival in end stage renal disease (ESRD)
patients on dialysis and therefore anti-HCV positivity should not be considered as an absolute
contraindication for renal transplantation (Natov & Periera, 2012; Knoll et al, 1997).
Figure 1. Kaplan-Meier estimate of the cumulative probability of patient survival. Reprinted from Transplantation Pro‐
ceedings, 38, 1890-1894 (2006), Pedroso S et al., Impact of Hepatitis C Virus on Renal Transplantation: Association
with Poor Survival. With permission from Elsevier through Copyright Clearance Center
Figure 2. Kaplan-Meier estimate of the cumulative probability of graft survival.Reprinted from Transplantation Pro‐
ceedings, 38, 1890-1894 (2006), Pedroso S et al., Impact of Hepatitis C Virus on Renal Transplantation: Association
with Poor Survival. With permission from Elsevier through Copyright Clearance Center
The increased morbidity and mortality in HCV infection is not only related to liver disease but
also extrahepatic complications (Kidney disease: improving global outcome [KDIGO], 2008).
HCV infection can predispose to the development of pre and posttransplant diabetes. A 2005
meta-analysis of 2502 patients noted a fourfold increase in the development of New Onset
Diabetes mellitus after Transplantation (NODAT) among HCV infected patients when
compared to the non-infected group (Gursoy et al., 2000; Abbott et al., 2004). It is suggested
Hepatitis C Infection in Kidney Transplantion
http://dx.doi.org/10.5772/55648
235
that HCV infection might be associated with increased insulin resistance contributing to
development of NODAT.
HCV has been associated with renal disease in both native and transplanted kidneys. It is in
fact reported to be more associated with glomerular disease in renal transplants than native
kidneys. This association is suggested to be secondary to immunosuppressive therapy leading
to increased HCV RNA titres (Periera et al., 1995; Burstein & Rodby, 1993). In renal transplant
recipients, HCV infection has been implicated in pathogenesis of acute glomerulopathy, de
novo immune complex glomerulonephritis in allograft, and chronic allograft nephropathy
(CAN) (Cosio et al., 1996; Roth et al., 1995; Ozdemir et al., 2006; Morales et al., 1997; Mahmoud
et al., 2005). De novo membranoproliferative glomerulonephritis (MPGN), and de novo
membranous glomerulonephritis (MGN), with or without mixed cryoglobulinemia are the
most frequent glomerular patterns of injury seen in association with HCV infection in renal
allografts. In 2001, one study reported the prevalence of de novo MPGN and MGN to be 45.4%
and 18.2% in HCV positive transplant recipients as compared to 5.7% and 7.7% in HCV
negative recipients (Cruzado et al., 2001). Subsequently, another study in 2006 reported the
prevalence of de novo GN to be 34% in HCV infected recipients and only 6.6% in HCV negative
recipients (Ozdemir et al., 2005). In general higher prevalence of autoimmune GN was
associated with poor graft outcome, and even worse than de novo GN in HCV negative patients
(Carbone et al., 2011).
Proteinuria is a common manifestation of kidney disease in HCV infected patients and renal
biopsy is used to establish the diagnosis of glomerular injury, however currently it is impos‐
sible to determine HCV as the cause of glomerular damage based solely on morphologic
assessment of renal biopsy. (Natov & Periera, 2012).
In 2005, Mahmoud et al reported a higher rate of CAN in HCV infected patients who did not
receive interferon (IFN) therapy prior to renal transplant. Recent data also shows increased
rate of graft failure due to CAN in HCV positive recipients than HCV negative (Scott et al.,
2010). The Spanish Chronic Allograft Nephropathy Group analyzed 4304 renal transplant
recipients with 587 of them being HCV positive over a period of 1990 to 2002. The study
reported HCV infection to be associated with early proteinuria, lower renal function, de novo
GN, chronic rejection, graft loss, and lower survival than HCV negative recipients (Morales et
al., 2010). Another implication of HCV infection is its association with development of early
graft dysfunction due to acute glomerular lesion. Examples of such lesions include acute
transplant glomerulopathy, and de novo renal thrombotic microangiopathy (Cosio et al.,
1996, Baid et al., 1995). Acute transplant glomerulopathy is mostly considered to be an atypical
variant of acute cellular rejection and is also present more commonly in HCV positive
recipients (Cosio et al., 1996a, 1996b).
3. Diagnosis
Detection of HCV infection is based primarily on the type of laboratory test used and its
sensitivity and specificity. Any false positive tests will lead to unnecessary waste of precious
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potential  organs for transplant (Natov & Periera,  2012).  A large collaborative study was
performed in United States that looked at the positive and negative predictive values of
antibody  screening  tests.  Eight  organ  procurement  organizations  representing  different
geographical  regions studied 3078 cadaver organ donors.  Using first  generation enzyme
linked immunosorbent assay ELISA1 anti-HCV test, the prevalence was found to be 5.1%
(1.5-16.7%). Using the second generation ELISA2, the prevalence was 4.2%, with positive
predictive value of 55% and negative predictive value of 100%. Some investigators have
suggested the use of  third generation ELISA3 tests to screen cadavers for HCV that be‐
cause  of  its  improved specificity  showed only  3.7% prevalence.  On the  other  hand,  the
prevalence of HCV RNA (ribonuclease acid) detection by Polymerase chain reaction (PCR)
was only 2.4%. Although discarding all ELISA2 positive organs would eliminate transmis‐
sion of HCV, there will be waste of 1.8% that will be discarded based on ELISA2 positivity
while they are HCV RNA negative. However, it is currently not practical to test cadavers for
HCV RNA status prior to organ procurement (Challine et al., 2004). The current practice in
major centers is still to screen organ donors for antibodies against HCV. The serum amino‐
transferase levels are usually normal in uremic patients, and therefore are not considered
reliable in determining disease activity and severity of fibrosis in this group. For clinically
suspicious patients with elevated serum aminotransferase levels but negative antibody test,
an HCV RNA assay with a detection limit of less than 50 IU/mL is recommended to rule out
infection (Pawlotsky, 2002).
There is limited data on the impact of different HCV genotypes on survival after transplanta‐
tion. Data reported by New England Organ Bank had relatively small number of patients and
HCV genotype distribution to reach a conclusion (Natov et al., 1999).
Liver biopsy remains the gold standard for assessment of liver damage and fibrosis. Several
scoring systems are used for assessment of hepatic fibrosis that use various criteria such as
activity index and special stains for collagen deposition. Examples of these scoring systems
include hepatic activity index (HAI), Knodell score and the Matavir system. Patients with HCV
infection can have evidence of histologic liver disease in the absence of elevated transaminases
and abnormal liver function tests. Therefore there may be merit in performing liver biopsy on
all anti-HCV positive patients on transplant wait list. In patients with histologic evidence of
liver disease, the decision to proceed or not with transplantation should be made with extreme
caution as post-transplant immunosuppression may exacerbate liver disease (Zylerberg et al.,
2002).
4. Clinical outcome with impact of HCV status before transplantation, and
use of allografts from HCV positive donors
HCV has multiple distinct variants that are classified into six major types based on the viral
genome sequence analysis. Each type consists of subtypes named in order of discovery such
as a,b, c and so on, the subtypes may include individual isolates. Repeated infection or
superinfection may occur in the same patient by the same or a different strain as HCV does
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not provide immunity. Thus transplant recipients that are positive for HCV RNA may have
the viral genotype of the donor, same genotype as present pretransplant or both individual
genotypes. The impact of superinfection is not clear, however there is some evidence that HCV
infection by one or multiple strains does not impact the survival negatively, at least in the short
term (Natov et al., 1999; Natov & Periera, 2012; Ali et al., 1998).
The use of renal allografts from HCV positive donors to be transplanted in HCV infected
recipients may offer some advantage (Figure 3) (Abbott et al., 2003). This approach is consistent
with 2008 Kidney Disease: Improving Global Outcomes (KDIGO) Guideline recommendations
(KDIGO, 2008). A survey was performed in United States on 245 transplant centers with
response obtained from 147 centers. The data showed that 49% of these centers use HCV
seropositive donors (Batiuk et al., 2002). Patients who are HCV positive before transplant have
a significantly higher risk of developing posttransplant liver disease, mainly chronic hepatitis
and its sequelae. An unusual serious form of liver involvement termed fibrosing cholestatic
hepatitis has been reported in such patients. it is characterized by severe cholestasis, extensive
fibrosis, and rapidly progressive liver failure, and is most likely related to acute infection under
maximum immunosuppression (Toth et al., 1998; Delladetsima et al., 2006). Kidney transplant
in HCV positive patients is associated with a 1.8-30.3 fold increase in serum viral titer most
likely due to increased viral proliferation secondary to immunosuppressive therapy. However,
this increase in viral titer may not be associated with increased risk of posttransplant liver
disease, neither does it have any association with transaminase pattern or histologic severity
of liver injury (Natov & Periera, 2012; Periera et al., 1995; Rpth et al., 1996).
Figure 3. Kaplan-Meier plot of patient survival after renal transplantation, limited to patients who received a kidney
positive for hepatitis C (DHCV+; n = 873) stratified by recipients who were HCV+ and HCV−. Reprinted from J Am Soc
Nephol, 14, 2908-2918 (2003), Abbott K et al., Hepatitis C and Renal Transplantation in the Era of Modern Immuno‐
suppression. With permission through Copyright Clearance Center
Mycophenolate mofetil and antithymocyte globulin are reported to increase HCV viremia
while cyclosporine was found to have a suppressive effect on HCV replicon RNA level and
HCV protein expression in cultured human hepatocytes (Figure 4) (Abbott et al., 2003; Rostaing
et al., 2000; Geith, 2011; Misiani et al., 1994).
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Figure 4. Kaplan-Meier plot of patient survival after renal transplantation, limited to patients who received a kidney
positive for hepatitis C (DHCV+; n = 873) stratified by recipients who received mycophenolate mofetil (MMF) or those
who did not (no MMF). Reprinted from J Am Soc Nephol, 14, 2908-2918 (2003), Abbott K et al., Hepatitis C and Renal
Transplantation in the Era of Modern Immunosuppression. With permission through Copyright Clearance Center
Although there is solid data that shows increased risk of developing liver disease in HCV
positive patients, there are conflicting reports and data regarding impact on survival. Some
studies failed to show any difference in overall survival in transplant recipients that were HCV
positive or negative. Other studies of pretransplant HCV positive recipients reported increased
mortality rate mainly due to liver disease and sepsis with a 3.3 fold increased risk of death and
9.9 fold higher risk of mortality due to sepsis (Natov & Periera, 2012; Periera et al., 1995;
Legendre et al., 1998). A 2005 meta-analysis on eight clinical trials involving a cohort of 6365
patients showed an increased relative risk of death in HCV positive patients (1.79) mainly due
to liver cirrhosis and cancer. In addition the relative risk of allograft failure was 1.56 (Fabrizi
et al., 2005).
Studies conducted in the 80s and 90s showed 35% of recipients who received allografts from
HCV positive donors developed posttransplant liver disease, 50% became anti HCV positive
after transplant, and 73% developed HCV viremia (Natov, 2002; Periera et al., 1994). The wide
variation in the rate of transmission could be related to different prevalence among donors,
difference in organ preservation and failure to test recipients in some centers. A large registry
analysis in 2002 showed increased mortality in recipients of allografts from HCV positive
donors regardless of the HCV status of the recipient (Bucci et al., 2002). Using the data from
the Organ Procurement and Transplantation Network (OPTN), Maluf reported approximately
300 days shortening of wait time for HCV positive recipients receiving allografts from HCV
positive donors compared with HCV negative recipients however there was significantly
decreased graft and patient overall survival (Maluf et al., 2010). A larger analysis of the same
data from OPTN was performed recently by Northup and colleagues in 2010 that included
19496 HCV positive recipients and 934 HCV positive donors. It showed the adjusted hazard
ratio for death to be similar for HCV positive recipients of HCV positive donors and HCV
positive recipients of HCV negative donors. The worst survival was seen in HCV negative
recipients who received allografts from HCV positive donors (Northup et al., 2010).
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In regards to superinfection, HCV genotype 1 is the most common genotype of HCV seen in
Western countries and is notorious to be less responsive to antiviral therapy including
Pegylated IFN and Ribavirin. Some authorities suggest that genotyping should be done
routinely and genotype 1 renal allografts should not be used in recipients with other genotypes.
However data is limited regarding this strategy (Carbone et al., 2011).
5. Treatment
In non-transplant setting, the combination therapy with interferon (IFN) and Ribavirin is the
standard of care for treatment of initial as well as relapse of HCV infection. Clearance of
Ribavirin is impaired in patients with renal dysfunction as the drug itself and its metabolites
cannot be removed by Hemodialysis. Therefore, Ribavirin is not recommended in patients
with creatinine clearance of less than 50mL/min. IFN therapy is however recommended in
dialysis patients. The goal of pretranslant HCV treatment is to attempt to eradicate HCV before
transplant subsequently leading to decrease in the risk of progression of HCV-associated liver
disease, reduced risk of posttransplant renal dysfunction, and possible reduction in HCV
disease progression. The optimal treatment of HCV in dialysis patients is regarded as IFN
therapy but it is not known whether there is any added advantage on the use of pegylated IFN
over nonpegylated standard IFN. Dialysis patients are not considered candidates of combi‐
nation therapy owing to concerns regarding development of Ribavirin-induced anemia as the
clearance of the drug is impaired in patients with renal dysfunction. A safer but less cost-
effective approach is to use IFN therapy to treat HCV positive patients on dialysis who are
potential transplant candidates. This strategy seems to have a beneficial effect on the course
of liver disease posttransplant, shows higher rates of sustained biochemical and virological
response, and seems to have reduced risk of HCV disease progression. At present data on
relapse rate on HCV positive patients treated pretransplant is limited and controversial. 2008
KDIGO guidelines suggest HCV positive transplant candidates to be considered for IFN
therapy before transplant. Ribavirin is not recommended because of its impaired clearance.
Similar concerns apply to pegylated IFN because of its longer half-life and is also not recom‐
mended for pretransplant HCV therapy.
Posttransplant HCV treatment is generally not recommended. A major limitation to the use of
IFN posttransplant is the potential of developing acute rejection. In addition to antiviral
activity, IFN also has pleiotropic effects including antiproliferative and immunomodulatory
functions. The National Institute of Health (NIH) Consensus Statement on management of
HCV infection lists renal transplant as one of the contraindications to IFN therapy. Most
authorities are in line with this approach because of the increased risk of acute rejection, high
cost, limited efficacy, and significant side effects that are reported with IFN treatment after
transplant. Treatment may be recommended in exceptional and life-threatening cases of HCV
complications such as fibrosing cholestatic hepatitis, life-threatening vasculitis, recurrent and
progressive HCV-associated glomerulopathy in the transplanted kidney, and advanced
histologic stages of liver fibrosis.
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2008 KDIGO guidelines recommend monotherapy with standard IFN only to be considered
in HCV positive kidney transplant recipients (Terraut & Adey, 2007; Kim et al., 2011; Carbone
et al., 2011; Natov & Periera, 2012. Data on efficacy of Ribavirin treatment alone after transplant
is limited. Combination therapy is the most likely regimen to achieve a sustained virologic
response (SVR), however Ribavirin dosage must be adjusted based on the renal function to
minimize the complication of anemia.
Large scale, multicenter clinical trials are needed to determine the optimal treatment approach
in these populations. New therapies may offer specific advantages and show decreased
incidence of treatment-related side effects than the currently available drugs.
In addition SVR to antiviral therapy in patients with HCV associated renal disease has been
associated with improvement in renal histology with reduced inflammation and immune
deposits. Recently, five HCV positive renal transplant patients who developed type III
cryoglobulinemic MPGN were successfully treated by Rituximab (anti-CD 20) chimeric
monoclonal antibody (Basse et al., 2005, 2006).
Transplantation after adequate antiviral therapy followed by minimal immunosuppression
can be a good option. Recently, Shah and colleagues evaluated graft function and graft as well
as patient survival in retrospective analyses of 132 HCV-positive renal transplant patients who
received tolerance induction protocol (TIP) with minimal immunosuppression and compared
them with 79 controls transplanted using standard triple immunosuppression drugs. TIP
consisted of 1 donor-specific transfusion, peripheral blood stem cell infusion, portal infusion
of bone marrow, and target-specific irradiation. In the TIP group patient survival at 1, 5, and
10 years was 92.4%, 70.4%, and 63.7%, respectively, versus 75.6%, 71.7%, and 55.7% in the
control group. The graft survival was 92.9%, 81.5%, and 79.1% versus 91.7%, 75.7%, and 67.7%,
respectively. Rejection episodes were less frequent in the former group. Abnormal liver
enzymes were seen in 22% patients in the TIP group versus 31% of the control group (Shah et
al., 2011).
6. Conclusion
HCV infection is relatively common among patients with ESRD on dialysis and kidney
transplant recipients. It is a major cause of morbidity and mortality among this group. When
indicated, treatment with IFN and antiviral therapy should be commenced prior to kidney
transplantation. The optimal treatment of transplant patients with HCV infection is not known.
IFN is not recommended posttransplant because of potential risk of rejection. However there
are some life threatening HCV related complications that would compel the use of IFN in a
renal transplant recipient. In conclusion, Ribavirin is contraindicated in dialysis patients and
alternative drugs are needed to enhance antiviral effects of IFN. For renal transplant recipients,
Ribavirin can be used in combination with IFN in patients with restored renal function,
however the risk of acute rejection with IFN therapy remains a serious concern. Alternative
drugs are also needed with better safety and efficacy for treatment of HCV posttransplant.
Despite the ongoing dilemma HCV positive renal transplant recipients have a better survival
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than HCV positive patients awaiting transplantation. Data shows strong evidence that use of
allografts from HCV positive donors leads to reduced wait time for HCV positive recipients
however there is conflicting data about graft and overall survival that needs to be further
studied. In addition transplant of kidneys from HCV positive donors should be restricted to
recipients with HCV viremia at the time of transplant.
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